CompletedPhase 2/3

Long-Term Study of MP-214 in Patients With Schizophrenia

Japan, South Korea, Taiwan254 participantsStarted 2012-09

Plain-language summary

The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with schizophrenia.

Who can participate

Age range20 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Written informed consent obtained from the patient before the completion of Study A002-A4 * Patients who have completed the A002-A4 study Exclusion Criteria: * Patients who are experiencing ongoing, uncontrolled, clinically significant adverse events (AEs), as judged by the investigator (or subinvestigator) The information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

What they're measuring

Number of Participants With Adverse Events as a Measure of Safety and Tolerability

Timeframe: Up to 60 weeks (Treatment Period (48 weeks) and Follow-up Period (12 weeks))

Trial details

NCT IDNCT01626872

SponsorTanabe Pharma Corporation

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2016-10

Results submitted2021-01-11

View on ClinicalTrials.gov More Schizophrenia trials